UNLIMITED TURBO BULL - MODERNA | Market Closed - Euronext Paris 12:30:00 2024-06-19 pm EDT | ||
| 5.3 EUR | -4.85% |
|
| Current month | -15.85% | ||
| 1 month | -3.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-19 | 5.31 | -4.67% |
| 24-06-18 | 5.57 | -7.17% |
| 24-06-17 | 6 | -0.99% |
| 24-06-14 | 6.06 | -8.73% |
| 24-06-13 | 6.64 | -2.21% |
Real-time Euronext Paris
Last update June 19, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| L744S | |
| ISIN | DE000SU5XKL0 |
| Date issued | 2023-12-18 |
| Strike | 75.04 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.45 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.81 € |
|---|---|
| Lowest since issue | 1.135 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Certificates
- L744S Certificat
